20 Jun 2026

CRC Research Update — June 20, 2026

Creator: The CRC Digest
Published: 2026-06-20T13:13:12Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Combining risk questionnaires with FIT may improve screening efficiency
A study of 14,327 adults in China compared four screening strategies using questionnaire-based risk assessment and fecal immunochemical tests, finding that parallel combinations (either test positive) detected more colorectal cancer and advanced adenomas than single-test approaches. (International Journal of Cancer)
Post-polypectomy surveillance may be overused in some patients
A new viewpoint in The Lancet Gastroenterology & Hepatology argues that current colonoscopy surveillance strategies after polyp removal may not optimally balance benefits and burdens, with some high-risk patients actually having low absolute risk of colorectal cancer. (The Lancet Gastroenterology & Hepatology)
Inflammation linked to persistent fatigue in colorectal cancer survivors
A study of 411 newly diagnosed colorectal cancer patients followed for two years found associations between inflammatory biomarkers and multiple dimensions of cancer-related fatigue, with both between-patient and within-patient effects observed. (International Journal of Cancer)
KRAS-mutant colorectal cancers show variable response to RAS inhibitors
Preclinical research found that KRAS-mutant colorectal cancer models respond differently to RAS(ON) inhibitor RMC-7977 based on PI3K signaling and cyclin D1 expression patterns, with combined RAS and PI3K inhibition showing synergistic effects in some tumors. (Cell Reports)

🔎 Screening Watch

Advances in early detection and prevention

Most people don't complete annual stool tests consistently
Among nearly 493,000 adults who completed an initial FIT or gFOBT, only 54% were consistent repeaters (≥75% of rounds completed) over ten years, while 30% were inconsistent. (Clinical Gastroenterology and Hepatology)
Blood-based DNA methylation test shows promise for early detection
A pilot study of 50 participants in Gaza evaluated circulating tumor DNA methylation biomarkers (SEPT9, SPG20, ALX4, MGMT, and RASSF1A) for non-invasive colorectal cancer detection, with multi-gene panels showing improved diagnostic performance. (Clinica Chimica Acta)

🧬 Biomarker Spotlight

Research by genetic subtype

Lynch syndrome prevalence varies by population and cancer type
A review of published studies found Lynch syndrome prevalence ranges from 0.7% to 4% among unselected colorectal cancer patients, with higher rates in selected high-risk patients and up to 5.9% in Canadian endometrial cancer patients. (International Journal of Cancer)
CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors
Preclinical research identified palbociclib as an unexpected suppressor of β-catenin signaling that synergizes with KRAS or ERK5 inhibition in colorectal cancer models. (Journal of Translational Medicine)

Research continues to refine screening strategies and uncover new treatment pathways—progress built one study at a time.

CRC Research Update

Subscribe to The CRC Digest